Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Chengdu Easton Biopharmaceuticals Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥33.62 |
52 Week High | CN¥43.71 |
52 Week Low | CN¥29.53 |
Beta | -0.035 |
11 Month Change | -11.78% |
3 Month Change | -12.84% |
1 Year Change | -9.85% |
33 Year Change | 9.56% |
5 Year Change | n/a |
Change since IPO | -33.86% |
Recent News & Updates
Why Chengdu Easton Biopharmaceuticals' (SHSE:688513) Shaky Earnings Are Just The Beginning Of Its Problems
May 01Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) Share Price Matching Investor Opinion
Mar 26Shareholder Returns
688513 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -3.9% | -0.1% | 0.4% |
1Y | -9.8% | -15.9% | -17.8% |
Return vs Industry: 688513 exceeded the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 688513 exceeded the CN Market which returned -17.8% over the past year.
Price Volatility
688513 volatility | |
---|---|
688513 Average Weekly Movement | 4.1% |
Pharmaceuticals Industry Average Movement | 5.5% |
Market Average Movement | 6.7% |
10% most volatile stocks in CN Market | 10.1% |
10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 688513 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688513's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 1,400 | Mingxu Yuan | www.eastonpharma.cn |
Chengdu Easton Biopharmaceuticals Co., Ltd. engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms in anesthetic/analgesics, cardiovascular, oncology, pediatrics, and other therapeutic fields. It also offers active pharmaceutical ingredients in oncology, cardiovascular, anesthetic/analgesics, anti-inflammatory, gastrointestinal, antiemetic, neurology/psychiatry, and urinary system therapeutic categories.
Chengdu Easton Biopharmaceuticals Co., Ltd. Fundamentals Summary
688513 fundamental statistics | |
---|---|
Market cap | CN¥5.90b |
Earnings (TTM) | CN¥240.60m |
Revenue (TTM) | CN¥1.15b |
24.4x
P/E Ratio5.1x
P/S RatioIs 688513 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688513 income statement (TTM) | |
---|---|
Revenue | CN¥1.15b |
Cost of Revenue | CN¥240.17m |
Gross Profit | CN¥914.09m |
Other Expenses | CN¥673.49m |
Earnings | CN¥240.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 20, 2024
Earnings per share (EPS) | 1.38 |
Gross Margin | 79.19% |
Net Profit Margin | 20.84% |
Debt/Equity Ratio | 7.6% |
How did 688513 perform over the long term?
See historical performance and comparison